SCHEMBL4202606

SCHEMBL4202606

O=c1c2sccc2nc(-c2ccc(F)cc2)n1NCc1ccc(Cl)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1I3 Q14994 3/20 0.43
RXFP1 Q9HBX9 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KMT2A Q03164 3/20 0.42
LMNA P02545 2/20 0.42
MEN1 O00255 2/20 0.42
MAPT P10636 3/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HTT P42858 1/20 0.38
CENPE Q02224 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
POLB P06746 2/20 0.36
NPC1 O15118 1/20 0.36
GLA P06280 1/20 0.36
RAB9A P51151 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4201045 0.89 RXFP1 (0.52) NR1I3RXFP1SMN1; SMN2KMT2ALMNA
SCHEMBL4201369 0.85 SMN1; SMN2 (0.44) RXFP1SMN1; SMN2KMT2ALMNAMEN1
SCHEMBL4198926 0.84 SMN1; SMN2 (0.44) NR1I3SMN1; SMN2KMT2ALMNAMEN1
SCHEMBL4194208 0.72 SMN1; SMN2 (0.46) NR1I3RXFP1SMN1; SMN2KMT2ALMNA
SCHEMBL4233295 0.72 SMN1; SMN2 (0.53) SMN1; SMN2KMT2ALMNAMEN1MAPT
SCHEMBL13602159 0.71 CASR (0.48) NR1I3SMN1; SMN2LMNAALDH1A1HTT
SCHEMBL4188977 0.71 MAPT (0.48) RXFP1SMN1; SMN2KMT2ALMNAMEN1
SCHEMBL4201010 0.70 SMN1; SMN2 (0.38) SMN1; SMN2LMNAMAPTALDH1A1HTT
SCHEMBL4237651 0.70 SMN1; SMN2 (0.67) SMN1; SMN2KMT2ALMNAMEN1MAPT
SCHEMBL4240608 0.69 SMN1; SMN2 (0.66) SMN1; SMN2KMT2ALMNAMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 GPBAR1, GPR119, GRK5 NR1I3 345/4885RXFP1 850/4885SMN1; SMN2 3183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.